COHEN & STEERS INC (CNS)
US19247A1007 - Common Stock
Taking everything into account, CNS scores 5 out of 10 in our fundamental rating. CNS was compared to 210 industry peers in the Capital Markets industry. Both the health and profitability get an excellent rating, making CNS a very profitable company, without any liquidiy or solvency issues. CNS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
CNS had positive earnings in the past year.
In the past year CNS had a positive cash flow from operations.
In the past 5 years CNS has always been profitable.
CNS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CNS has a Return On Assets of 17.52%. This is amongst the best in the industry. CNS outperforms 97.60% of its industry peers.
With an excellent Return On Equity value of 33.85%, CNS belongs to the best of the industry, outperforming 96.15% of the companies in the same industry.
CNS's Return On Invested Capital of 24.26% is amongst the best of the industry. CNS outperforms 97.12% of its industry peers.
CNS had an Average Return On Invested Capital over the past 3 years of 39.03%. This is significantly above the industry average of 8.34%.
The last Return On Invested Capital (24.26%) for CNS is well below the 3 year average (39.03%), which needs to be investigated, but indicates that CNS had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.52% | ||
| ROE | 33.85% | ||
| ROIC | 24.26% |
ROA(3y)28.61%
ROA(5y)28.25%
ROE(3y)55.79%
ROE(5y)54.86%
ROIC(3y)39.03%
ROIC(5y)41.91%
1.3 Margins
The Profit Margin of CNS (26.36%) is better than 60.10% of its industry peers.
CNS's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 33.59%, CNS perfoms like the industry average, outperforming 56.73% of the companies in the same industry.
In the last couple of years the Operating Margin of CNS has declined.
CNS's Gross Margin of 88.94% is amongst the best of the industry. CNS outperforms 89.90% of its industry peers.
CNS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.59% | ||
| PM (TTM) | 26.36% | ||
| GM | 88.94% |
OM growth 3Y-2.76%
OM growth 5Y-2.73%
PM growth 3Y13.73%
PM growth 5Y-2.48%
GM growth 3Y0.84%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
CNS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CNS has been increased compared to 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CNS has an Altman-Z score of 7.08. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.08, CNS belongs to the best of the industry, outperforming 92.79% of the companies in the same industry.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.08 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 1.15 indicates that CNS should not have too much problems paying its short term obligations.
CNS's Current ratio of 1.15 is in line compared to the rest of the industry. CNS outperforms 50.48% of its industry peers.
A Quick Ratio of 1.15 indicates that CNS should not have too much problems paying its short term obligations.
CNS has a Quick ratio (1.15) which is in line with its industry peers.
CNS does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.15 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
CNS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.72%.
The Earnings Per Share has been growing slightly by 3.27% on average over the past years.
Looking at the last year, CNS shows a very negative growth in Revenue. The Revenue has decreased by -13.63% in the last year.
Measured over the past years, CNS shows a small growth in Revenue. The Revenue has been growing by 5.14% on average per year.
EPS 1Y (TTM)-23.72%
EPS 3Y3.13%
EPS 5Y3.27%
EPS growth Q2Q-15.19%
Revenue 1Y (TTM)-13.63%
Revenue growth 3Y4.63%
Revenue growth 5Y5.14%
Revenue growth Q2Q-4.9%
3.2 Future
CNS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.02% yearly.
Based on estimates for the next years, CNS will show a decrease in Revenue. The Revenue will decrease by -3.84% on average per year.
EPS Next Y10.52%
EPS Next 2Y10.21%
EPS Next 3Y5.98%
EPS Next 5Y2.02%
Revenue Next Year4.31%
Revenue Next 2Y5.28%
Revenue Next 3Y3.59%
Revenue Next 5Y-3.84%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 24.58, which indicates a rather expensive current valuation of CNS.
71.63% of the companies in the same industry are cheaper than CNS, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CNS to the average of the S&P500 Index (25.25), we can say CNS is valued inline with the index average.
CNS is valuated rather expensively with a Price/Forward Earnings ratio of 22.24.
67.31% of the companies in the same industry are cheaper than CNS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.67. CNS is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.58 | ||
| Fwd PE | 22.24 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than 64.42% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CNS is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.97 | ||
| EV/EBITDA | 19.57 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)2.34
PEG (5Y)7.53
EPS Next 2Y10.21%
EPS Next 3Y5.98%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.30%. Purely for dividend investing, there may be better candidates out there.
CNS's Dividend Yield is comparable with the industry average which is at 7.77.
Compared to an average S&P500 Dividend Yield of 2.45, CNS pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.3% |
5.2 History
The dividend of CNS decreases each year by -9.78%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend recently.
Dividend Growth(5Y)-9.78%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
87.13% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP87.13%
EPS Next 2Y10.21%
EPS Next 3Y5.98%
COHEN & STEERS INC
NYSE:CNS (4/25/2024, 9:13:25 AM)
69.56
-1.23 (-1.74%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.45B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.3% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.58 | ||
| Fwd PE | 22.24 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.34
PEG (5Y)7.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.52% | ||
| ROE | 33.85% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 33.59% | ||
| PM (TTM) | 26.36% | ||
| GM | 88.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.15 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-23.72%
EPS 3Y3.13%
EPS 5Y
EPS growth Q2Q
EPS Next Y10.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-13.63%
Revenue growth 3Y4.63%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y